CASP7 and breast cancer: The combination of nelfinavir and dimethylcelecoxib (DMC)—a close structural analog of celecoxib that lacks cyclooxigenase-2 (COX2) inhibitory function—resulted in enhanced cleavage of caspase-7 and PARP in breast cancer cells [40].